🔴 Beam Therapeutics is trading 10.17% down today as biotech stocks slide

Beam Therapeutics is trading at $24.96, down 10.17%, amid a steep November 5 selloff and biotech weakness.

• XBI was down 5.19% in the supplied sector context.
• Reuters reported a sharp technology-sector retreat amid renewed concerns about AI regulation and data-center construction. Nasdaq reported Beam’s stock down 9.14% at 12:25 p.m. ET; the supplied live price is authoritative.
• The November 3 report showed a revenue miss and wider loss, but no source directly links those results to this session’s decline.